Department of Medicine, University of California San Diego, La Jolla, California.
Department of Medicine, VA San Diego Healthcare System, San Diego, California.
Infect Control Hosp Epidemiol. 2021 Jan;42(1):51-56. doi: 10.1017/ice.2020.375. Epub 2020 Sep 18.
Lack of judicious testing can result in the incorrect diagnosis of Clostridioides difficile infection (CDI), unnecessary CDI treatment, increased costs and falsely augmented hospital-acquired infection (HAI) rates. We evaluated facility-wide interventions used at the VA San Diego Healthcare System (VASDHS) to reduce healthcare-onset, healthcare-facility-associated CDI (HO-HCFA CDI), including the use of diagnostic stewardship with test ordering criteria.
We conducted a retrospective study to assess the effectiveness of measures implemented to reduce the rate of HO-HCFA CDI at the VASDHS from fiscal year (FY)2015 to FY2018.
Measures executed in a stepwise fashion included a hand hygiene initiative, prompt isolation of CDI patients, enhanced terminal room cleaning, reduction of fluoroquinolone and proton-pump inhibitor use, laboratory rejection of solid stool samples, and lastly diagnostic stewardship with C. difficile toxin B gene nucleic acid amplification testing (NAAT) criteria instituted in FY2018.
From FY2015 to FY2018, 127 cases of HO-HCFA CDI were identified. All rate-reducing initiatives resulted in decreased HO-HCFA cases (from 44 to 13; P ≤ .05). However, the number of HO-HCFA cases (34 to 13; P ≤ .05), potential false-positive testing associated with colonization and laxative use (from 11 to 4), hospital days (from 596 to 332), CDI-related hospitalization costs (from $2,780,681 to $1,534,190) and treatment cost (from $7,158 vs $1,476) decreased substantially following the introduction of diagnostic stewardship with test criteria from FY2017 to FY2018.
Initiatives to decrease risk for CDI and diagnostic stewardship of C. difficile stool NAAT significantly reduced HO-HCFA CDI rates, detection of potential false-positives associated with laxative use, and lowered healthcare costs. Diagnostic stewardship itself had the most dramatic impact on outcomes observed and served as an effective tool in reducing HO-HCFA CDI rates.
不合理的检测可能导致艰难梭菌感染(CDI)的误诊、不必要的 CDI 治疗、成本增加和虚假的医院获得性感染(HAI)率增加。我们评估了退伍军人事务部圣地亚哥医疗保健系统(VASDHS)在降低医疗保健相关性、医疗机构相关 CDI(HO-HCFA CDI)方面使用的全院范围的干预措施,包括使用诊断管理和检测订单标准。
我们进行了一项回顾性研究,以评估从 2015 财年到 2018 财年在 VASDHS 实施的降低 HO-HCFA CDI 率的措施的有效性。
逐步执行的措施包括手部卫生倡议、及时隔离 CDI 患者、加强终末房间清洁、减少氟喹诺酮类药物和质子泵抑制剂的使用、实验室拒收固体粪便样本,以及最后在 2018 财年实施的艰难梭菌毒素 B 基因核酸扩增检测(NAAT)标准的诊断管理。
从 2015 财年到 2018 财年,确定了 127 例 HO-HCFA CDI 病例。所有降低发病率的举措均导致 HO-HCFA 病例减少(从 44 例降至 13 例;P ≤.05)。然而,HO-HCFA 病例数量(从 34 例降至 13 例;P ≤.05)、与定植和泻药使用相关的潜在假阳性检测(从 11 例降至 4 例)、住院天数(从 596 天降至 332 天)、CDI 相关住院费用(从 2780681 美元降至 1534190 美元)和治疗费用(从 7158 美元降至 1476 美元)在 2017 财年至 2018 财年实施诊断管理和检测标准后大幅下降。
降低 CDI 风险的举措和艰难梭菌粪便 NAAT 的诊断管理显著降低了 HO-HCFA CDI 率,降低了与泻药使用相关的潜在假阳性检测的检出率,并降低了医疗保健成本。诊断管理本身对观察到的结果产生了最显著的影响,并成为降低 HO-HCFA CDI 率的有效工具。